Skip to main content
Premium Trial:

Request an Annual Quote

Caprion and Ecopia Raise $45M in Merger Financing

NEW YORK (GenomeWeb News) — Ecopia BioSciences and Caprion Pharmaceuticals today said they received $45 million in a private placement tied to their merger.
The firms had said they expected to raise between $30 million and $45 million in the placement, which is being handled by the securities companies Desjardins and Dundee.  
The companies said they will use the funding for drug development after they complete their merger to form a new company to be called Thallion Pharmaceuticals. The firms had planned to call the new company Amalco.
As GenomeWeb News reported in January, the companies said they plan to divest Caprion’s CellCarta proteomics unit in 2007, which would leave Thallion to focus on oncology and infectious disease therapeutics.
Caprion President and CEO Lloyd Segal will serve as CEO of the new company.
Ecopia President and CEO Pierre Falardeau said the funds from the offering will “allow Thallion to drive the development of all thee of its clinical products.”

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.